Loading...
TrendSpott

TrendSpott

TrendSpott
 
 
Esperion Therapeutic
1.59
-4.79%
 
Recommendation
ESPR Esperion Therapeutics
  Login
 
 
Last Price
 
Change
 
1.59
 
-4.79%
 
 

 
Sentiment
 
  Login to display
 
 

5.59

6.3

6.99

5.99

 
 
1m
3m
6m
1y
 

Summary

  Login to display Esperion Therapeutics (ESPR) recommendation from the last 90 days from financial news and social media.
 

Risk Analysis

Risk Analysis

 Enter oversold territory

Risk Analysis

 Earnings are forecast to decrease

 
 

Risk Level

 
TrendSpott
 

Esperion Therapeutics (ESPR) has Medium Risk Level

Click here to check what is your level of risk

 

Analysts Opinion

Click on the category for more information
 
 
Earnings ×
 

Earnings

2.00
 

TrendSpott

 Below analyst estimate

 
 
Rating ×
 

Rating

2.33
 
 
Momentum ×
 

Momentum

2.38
 

TrendSpott

 Price value has negative momentum

TrendSpott

 Enter oversold territory

 
Activity ×
 

Activity

4.00
 

TrendSpott

 Debt capital raise

 
Future ×
 

Future

1.00
 

TrendSpott

 Earnings are forecast to decrease

 
 

Analysts Opinion

Analysts opinion is negative but has improved from the past 3 months

 

Street Consensus

Buy
Opinion
Trend
Score
Potential
Score
 
52%
33%
0%
0%
 
On Track
On Track
On Track
 

Street Opinion 

Street view is bullish but have mixed views on the near-term outlook

 
Events Rating
 
Very Bullish
Bullish
Neutral
Bearish
Very Bearish
 
Positive vs Negative
 
52%
39%
Positive
Negative
17 out of 33
events present
13 out of 33
events present
 

 
Events Calendar
Click for more information
 
February
S
M
T
W
T
F
S
March
S
M
T
W
T
F
S
 
Highlights
Last
Modify
Closing
Price
%
Change
 
Capital Raise
1 Week Ago
1.54
-0.65%
 
Downgrade
2 Weeks Ago
1.82
-54.27%
 
Upgrade
3 Weeks Ago
4.91
-3.35%
 
Weak Earnings
2 Month Ago
5.69
+1.79%
 
Weak Earnings
2 Month Ago
5.59
-5.57%
 
Top Headlines

esperion in red on pricing $56.7m in stock and short-term warrants offering.

Mon Mar 20, 2023

Activity

esperion (espr) plummets 54% over milestone payment row. the share price of esperion therapeutics espr lost 54.3% on mar 16 after management reported a disagreement with one of its partners over certain milestone payments.

Fri Mar 17, 2023

Activity

why esperion therapeutics stock is tanking thursday. ) shares are plummeting thursday after the company reported a disagreement with one of its partners over . said itbelieves it'.sentit

Thu Mar 16, 2023

Activity
Momentum

northland downgrades esperion to underperform pt $1 uncertainty surrounding esprs receipt of $300mm milestone payments.

Thu Mar 16, 2023

Activity
Potential
Rating

esperion extends selloff as daiichi sankyo dispute prompts bofa downgrade.

Thu Mar 16, 2023

Momentum
Rating

esperions stock tumbles after disclosing dispute about milestone payment.

Thu Mar 16, 2023

Activity
Momentum

liveperson amyris and other big stocks moving lower in thursdays pre-market session. United States stock futures traded mixed this morning. here are some big stocks recording losses in today&rsquo.s pre-market trading session. ) dropped 50.3% to $1.98

Thu Mar 16, 2023

Activity

esperion therapeutics falls 55% in dustup with daiichi sankyo over milestone payments.

Wed Mar 15, 2023

Activity

credit suisse upgrades esperion therapeutics (espr). on march 7 2023 credit suisse upgraded their outlook for esperion therapeutics (nasdaq:espr) from underperform to neutral.

Tue Mar 7, 2023

Rating
Rating

esperion upgraded at credit suisse despite selloff after nexletol data.

Tue Mar 7, 2023

Momentum
Rating

esperion (espr) q4 loss narrows revenues miss stock down. esperion therapeutics espr incurred a loss per share of 76 cents per share in the fourth quarter of 2022 narrower than the zacks consensus estimate as well as our estimate of a

Wed Feb 22, 2023

Earnings
Momentum

esperion therapeutics (espr) reports q4 loss misses revenue estimates. esperion therapeutics (espr) came out with a quarterly loss of $0.76 per share versus the zacks consensus estimate of a loss of $0.87. this compares to loss of $1.7

Tue Feb 21, 2023

Earnings

esperion therapeutics gaap eps of -$0.76 beats by $0.09 revenue of $18.8m misses by $1.8m.

Tue Feb 21, 2023

Earnings

esperion outlines upcoming milestones and announces preliminary fourth quarter 2022 financial results. – based on the robustness of the clear outcomes data across primary and secondary endpoints company anticipates global regulatory submissions in 1h 20

Mon Jan 9, 2023

Activity

 
 
 
TrendSpott

Get all the pieces of the puzzle on important data activity before the major news sources break the story and find out what happening right now and what could happen in the future

FIND US ON

TrendSpott on Twitter TrendSpott on YouTube TrendSpott on stocktwits TrendSpott Rss
 

Receive our daily ESPR alerts

Enter your email to receive daily alerts

 
Home

Leading Gainers

Upgrades

Downgrades

Top Leaders

 
Categories

Ipo's

Dividend

Option Activity

Insiders Activity

Institutional Holdings

 
Tags

New Products

FDA Approvals

Agreements

Financial Reports

 
About Us

Log In

Sign Up

Contact Us

Terms of use

Privacy Policy

 
 

Disclaimer: The Score performance whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The Readiness Indicators, Sentiment Indicators and total score are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. Active trading is generally not appropriate for someone of limited resources, limited invesment or trading experience, or low-risk tolerance. Your capital may be at risk.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by TrendSpott including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

 
TrendSpott

TrendSpott

Get the pulse of the market

 
TrendSpott

TrendSpott

ESPR Esperion Therapeutics

Last Price
1.59
Change
-4.79%
Recommendation
  Login to display
 

Summary

  Login to display Esperion Therapeutics (ESPR) recommendation from the last 90 days from financial news and social media.

 
 
5.59
6.3
6.99
5.99
 
 
1m
3m
6m
1y
 
Sentiment
 

  Login to display

Risk Analysis

Risk Analysis

 Enter oversold territory

Risk Analysis

 Earnings are forecast to decrease

 
 
 
 
Street Consensus
 
Buy
Opinion
Trend
Score
Potential
Score
 
33%
0%
0%
On Track
On Track
On Track
 
52%
39%
Positive
Negative
17 out of 33
events present
13 out of 33
events present
 

Street Opinion

Street view is bullish but have mixed views on the near-term outlook

 
 
Analysts Opinion
Hover the category for more information
 
 
Earnings ×
 

Earnings

2.00
 

TrendSpott

 Below analyst estimate

 
 
Rating ×
 

Rating

2.33
 
 
Momentum ×
 

Momentum

2.38
 

TrendSpott

 Price value has negative momentum

TrendSpott

 Enter oversold territory

 
Activity ×
 

Activity

4.00
 

TrendSpott

 Debt capital raise

 
Future ×
 

Future

1.00
 

TrendSpott

 Earnings are forecast to decrease

 
 

Analysts Opinion

Analysts opinion is negative but has improved from the past 3 months

 
 
 
 
 
Events Rating
 
Very Bullish
Bullish
Neutral
Bearish
Very Bearish
 
 
Risk Level
 
TrendSpott
 

Esperion Therapeutics (ESPR) has Medium Risk Level.  Click here to check what is your level of risk

 
 
 

Events Calendar

Hover for information

 
February
 
S
M
T
W
T
F
S
 
March
 
S
M
T
W
T
F
S
 
 
 
 
Highlights
Last
Modify
Closing
Price
%
Change
 
Capital Raise
1 Week Ago
1.54
-0.65%
 
Downgrade
2 Weeks Ago
1.82
-54.27%
 
Upgrade
3 Weeks Ago
4.91
-3.35%
 
Weak Earnings
2 Month Ago
5.69
+1.79%
 
Weak Earnings
2 Month Ago
5.59
-5.57%
 
 
 
TrendSpott

Get all the pieces of the puzzle on important data activity before the major news sources break the story and find out what happening right now and what could happen in the future

FIND US ON

TrendSpott on Twitter TrendSpott on YouTube TrendSpott on stocktwits TrendSpott Rss

 

Receive our daily ESPR Alerts

Enter your email to receive daily alerts

 
Home

Leading Gainers

Upgrades

Downgrades

Top Leaders

Categories

Ipo's

Dividend

Option Activity

Insiders Activity

Institutional Holdings

Tags

New Products

FDA Approvals

Agreements

Financial Reports

 
 

Disclaimer: The Score performance whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The Readiness Indicators, Sentiment Indicators and total score are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. Active trading is generally not appropriate for someone of limited resources, limited invesment or trading experience, or low-risk tolerance. Your capital may be at risk.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by TrendSpott including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

 
 
 
 
 

Top Headlines